288330 — Bridge Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- KR₩61bn
- KR₩52bn
- KR₩100m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 58,283 | 6,340 | 1,924 | 3,024 | 100 |
Cost of Revenue | |||||
Gross Profit | 22,289 | -1,113 | 758 | — | 33.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 57,666 | 25,918 | 28,316 | 46,525 | 40,449 |
Operating Profit | 617 | -19,578 | -26,392 | -43,501 | -40,349 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7,226 | -19,232 | -26,278 | -41,700 | -42,455 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,325 | -19,232 | -26,278 | -41,700 | -42,455 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,325 | -19,232 | -26,278 | -41,700 | -42,321 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,325 | -19,232 | -26,278 | -41,700 | -42,321 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 125 | -880 | -1,173 | -1,833 | -1,796 |
Dividends per Share |